So far, Cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), and the PD-1 inhibitors Nivolumab and Pembrolizumab have been approved for the treatment of clinically advanced HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.